<DOC>
	<DOC>NCT01754974</DOC>
	<brief_summary>The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus Ribavirin.</brief_summary>
	<brief_title>Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic hepatitis C, Genotype 1 HCV RNA ≥100,000 IU/mL at screening Liver biopsy documenting no cirrhosis (within prior 3 years). Where approved for staging of liver disease, noninvasive imaging may be used to assess the extent of liver disease Naïve to prior antiHCV therapy Infected with HCV other than Genotype 1 Positive Hepatitis B Surface Antigen (HBsAg), or Human Immunodeficiency Virus (HIV)1/HIV2 antibody at screening Evidence of liver disease other than HCV Active substance abuse Use of hematologic growth factors within 90 days prior to study randomization Evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>